Show simple item record

Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease

dc.rights.licenseopenen_US
dc.contributor.authorVILLAIN, Cédric
dc.contributor.authorMETZGER, Marie
dc.contributor.authorLIABEUF, Sophie
dc.contributor.authorHAMROUN, Aghilès
dc.contributor.authorLAVILLE, Solene
dc.contributor.authorMANSENCAL, Nicolas
dc.contributor.authorCOMBE, Christian
ORCID: 0000-0002-0360-573X
IDREF: 58708871
dc.contributor.authorFOUQUE, Denis
dc.contributor.authorFRIMAT, Luc
dc.contributor.authorJACQUELINET, Christian
dc.contributor.authorLAVILLE, Maurice
dc.contributor.authorAYAV, Carole
dc.contributor.authorBRIANÇON, Serge
dc.contributor.authorPECOITS-FILHO, Roberto
dc.contributor.authorHANNEDOUCHE, Thierry
dc.contributor.authorSTENGEL, Bénédicte
dc.contributor.authorMASSY, Ziad A.
dc.contributor.authorAYAV, Carole
dc.contributor.authorBRIANÇON, Serge
dc.contributor.authorCANNET, Dorothée
dc.contributor.authorCOMBE, Christian
ORCID: 0000-0002-0360-573X
IDREF: 58708871
dc.contributor.authorFOUQUE, Denis
dc.contributor.authorFRIMAT, Luc
dc.contributor.authorHERPE, Yves-Edouard
dc.contributor.authorJACQUELINET, Christian
dc.contributor.authorLAVILLE, Maurice
dc.contributor.authorMASSY, Ziad A.
dc.contributor.authorPASCAL, Christophe
dc.contributor.authorROBINSON, Bruce M.
dc.contributor.authorSTENGEL, Bénédicte
dc.contributor.authorLANGE, Céline
dc.contributor.authorLEGRAND, Karine
dc.contributor.authorLIABEUF, Sophie
dc.contributor.authorMETZGER, Marie
dc.contributor.authorSPEYER, Elodie
dc.contributor.authorHANNEDOUCHE, Thierry
dc.contributor.authorMOULIN, Bruno
dc.contributor.authorMAILLIEZ, Sébastien
dc.contributor.authorLEBRUN, Gaétan
dc.contributor.authorMAGNANT, Eric
dc.contributor.authorCHOUKROUN, Gabriel
dc.contributor.authorDEROURE, Benjamin
dc.contributor.authorLACRAZ, Adeline
dc.contributor.authorLAMBREY, Guy
dc.contributor.authorBOURDENX, Jean Philippe
dc.contributor.authorESSIG, Marie
dc.contributor.authorLOBBEDEZ, Thierry
dc.contributor.authorAZAR, Raymond
dc.contributor.authorSEKHRI, Hacène
dc.contributor.authorSMATI, Mustafa
dc.contributor.authorJAMALI, Mohamed
dc.contributor.authorKLEIN, Alexandre
dc.contributor.authorDELAHOUSSE, Michel
hal.structure.identifierBioingénierie tissulaire [BIOTIS]
dc.contributor.authorCOMBE, Christian
ORCID: 0000-0002-0360-573X
IDREF: 58708871
dc.contributor.authorMARTIN, Séverine
dc.contributor.authorLANDRU, Isabelle
dc.contributor.authorTHERVET, Eric
dc.contributor.authorMASSY, Ziad A.
dc.contributor.authorLANG, Philippe
dc.contributor.authorBELENFANT, Xavier
dc.contributor.authorURENA, Pablo
dc.contributor.authorVELA, Carlos
dc.contributor.authorFRIMAT, Luc
dc.contributor.authorCHAUVEAU, Dominique
dc.contributor.authorPANESCU, Viktor
dc.contributor.authorNOEL, Christian
dc.contributor.authorGLOWACKI, François
dc.contributor.authorHOFFMANN, Maxime
dc.contributor.authorHOURMANT, Maryvonne
dc.contributor.authorBESNIER, Dominique
dc.contributor.authorTESTA, Angelo
dc.contributor.authorKUENTZ, François
dc.contributor.authorZAOUI, Philippe
dc.contributor.authorCHAZOT, Charles
dc.contributor.authorJUILLARD, Laurent
dc.contributor.authorBURTEY, Stéphane
dc.contributor.authorKELLER, Adrien
dc.contributor.authorKAMAR, Nassim
dc.contributor.authorFOUQUE, Denis
dc.contributor.authorLAVILLE, Maurice
dc.date.accessioned2023-04-28T09:09:50Z
dc.date.available2023-04-28T09:09:50Z
dc.date.issued2022-06-01
dc.identifier.issn1525-8610en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/173221
dc.description.abstractEnObjectives Renin-angiotensin system inhibitors (RASi) are recommended for slowing chronic kidney disease (CKD) progression to kidney failure. Their effectiveness and tolerance as patients age remain uncertain because older patients have often been excluded from clinical trials. Design CKD-REIN cohort study. Setting and Participants We studied 2762 patients with CKD stages 3 and 4 and a clinical indication for RASi enrolled between 2013 and 2016 in 40 nephrology clinics nationally representative in France. Methods The primary outcome was the occurrence of kidney failure or death. The secondary outcomes were the occurrence of cardiovascular events and hospitalizations with acute kidney injury (AKI) or hyperkalemia. A propensity score analysis was performed. We used Cox models to estimate hazard ratios (HRs) for each outcome associated with RASi prescription and tested interactions with age. Results Patients' mean age was 67 years, including 841 (30%) aged 75 years and older; 2178 (79%) were prescribed RASi's. During a median follow-up of 4.6 years, 33% of patients reached kidney failure or died. RASi prescription was associated with a lower risk of kidney failure or death (HR 0.79, 95% CI 0.66, 0.95), an association not modified by age (P for interaction = .72). It was not significantly associated with cardiovascular events. During the first 3 years of follow-up, 14% of patients were hospitalized with AKI or hyperkalemia, but risk was not higher among those prescribed RASi's (HR 0.75, 95% CI 0.55-1.02) and age did not modify its effect (P for interaction = .28). Conclusions and Implications This study shows that aging does not appear to modify either RASi's beneficial effects on major CKD outcomes or their potential adverse effects.
dc.language.isoENen_US
dc.subject.enchronic kidney disease
dc.subject.enpropensity score analysis
dc.subject.enRenin-angiotensin system inhibitors
dc.title.enEffectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease
dc.title.alternativeJ Am Med Dir Assocen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.jamda.2021.10.019en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
bordeaux.journalJournal of the American Medical Directors Associationen_US
bordeaux.page998-1004.e7en_US
bordeaux.volume23en_US
bordeaux.hal.laboratoriesBioingénierie Tissulaire (BioTis) - U1026en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCHU de Bordeauxen_US
bordeaux.institutionInstitut Bergoniéen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20the%20American%20Medical%20Directors%20Association&rft.date=2022-06-01&rft.volume=23&rft.issue=6&rft.spage=998-1004.e7&rft.epage=998-1004.e7&rft.eissn=1525-8610&rft.issn=1525-8610&rft.au=VILLAIN,%20C%C3%A9dric&METZGER,%20Marie&LIABEUF,%20Sophie&HAMROUN,%20Aghil%C3%A8s&LAVILLE,%20Solene&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record